Protease inhibitor ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
265脂肪萎縮症6

265. 脂肪萎縮症


臨床試験数 : 112 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00656175
(ClinicalTrials.gov)
September 20082/4/2008Raltegravir Therapy for Women With HIV and Fat AccumulationPhase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat AccumulationHIV Infections;LipodystrophyDrug: raltegravirUniversity of California, Los AngelesMerck Sharp & Dohme Corp.;Case Western Reserve University;Vanderbilt University;Tufts University;University Health Network, TorontoCompleted18 YearsN/AFemale39Phase 2United States;Canada
2NCT00135356
(ClinicalTrials.gov)
July 200525/8/2005Study of Reyataz in HIV-infected Patients With Lipodystrophy SyndromeA Phase IV, Open-Label, Randomized, Multicenter Trial Assessing a Reyataz-Based Substitution Approach in the Management of Lipodystrophy Syndrome. Research Into Atazanavir in Lipodystrophy (The REAL Study)HIV-Associated Lipodystrophy SyndromeDrug: Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs);Drug: continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)Bristol-Myers SquibbNULLCompleted18 YearsN/AAll219Phase 4United States;Canada;France;Germany;Italy;Mexico;Poland;Spain;United Kingdom;Netherlands
3NCT00122668
(ClinicalTrials.gov)
November 200321/7/2005Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive PatientsRandomized Comparative Study Evaluating the Rate of Occurrence of a Lipoatrophy Syndrome in ARVnaive HIV-1 Infected Patients Receiving NRTI-Sparing Antiretroviral Regimen (Hippocampe - ANRS 121)HIV Infections;HIV-Associated Lipodystrophy SyndromeDrug: non-nucleoside reverse transcriptase inhibitors;Drug: nucleoside reverse transcriptase inhibitors;Drug: protease inhibitorFrench National Agency for Research on AIDS and Viral HepatitisNULLTerminated18 YearsN/ABoth112Phase 4France
4NCT00021463
(ClinicalTrials.gov)
April 200114/7/2001Changing to Nonprotease Inhibitor Treatment to Improve Side EffectsPhase II, Randomized, Open-Label Study of Switching to Protease Inhibitor-Sparing Regimens for Improvement of Metabolic AbnormalitiesHIV Infections;LipodystrophyDrug: Abacavir sulfate, Lamivudine and Zidovudine;Drug: Abacavir sulfate;Drug: Efavirenz;Drug: NevirapineNational Institute of Allergy and Infectious Diseases (NIAID)NULLCompleted13 YearsN/ABoth342Phase 2United States
5NCT00122655
(ClinicalTrials.gov)
January 200121/7/2005Study Evaluating the Impact on Fat Distribution of Nucleoside Reverse Transcriptase Inhibitor (NRTI)-Sparing Regimens in Antiretroviral Experienced Patients With LipoatrophyA Randomized Prospective Study Evaluating the Impact on Fat Distribution of NRTI-Sparing Regimens in Antiretroviral Experienced Patients With Lipoatrophy ANRS 108 NONUKE StudyHIV Infections;HIV Lipodystrophy SyndromeDrug: non-nucleoside reverse transcriptase inhibitors;Drug: nucleoside reverse transcriptase inhibitors;Drug: protease inhibitorsFrench National Agency for Research on AIDS and Viral HepatitisNULLTerminated18 YearsN/ABoth100Phase 4France
6NCT00002417
(ClinicalTrials.gov)
March 19982/11/1999A Study of Amprenavir in Patients With Protease Inhibitor-Related ComplicationsAn Open-Label Study to Evaluate the Safety and Tolerance of Amprenavir (141W94) Combination Therapy in Protease Inhibitor Experienced Subjects Who Are Intolerant (Hyperlipidemia With or Without Lipodystrophy) But Not Failing Their Current Protease Inhibitor TherapyHIV InfectionsDrug: AmprenavirGlaxo WellcomeNULLCompleted13 YearsN/ABothN/AUnited States